Evidence map›Paper›PMID 31227023›Full record

ArticleCancer communications (London, England)2019

Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression.

Jie Wang, Jianzhong Xi, Hanshuo Zhang, Juan Li, Yuchao Xia, Ruibin Xi, Zhijun Xi

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jie WangDepartment of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, No 8, Xishiku Street, Xicheng District, Beijing, 100034, P. R. China.
Jianzhong XiDepartment of Biomedical Engineering, College of Engineering, Peking University, Beijing, 100871, P. R. China.
Hanshuo ZhangBeijing Genex Health Technology Co., Ltd, Beijing, 100195, P. R. China.
Juan LiDepartment of Biomedical Engineering, College of Engineering, Peking University, Beijing, 100871, P. R. China.
Yuchao XiaChongqing Institute of Innovation and Entrepreneurship for Precision Medicine, Chongqing, 401336, P. R. China.
Ruibin XiSchool of Mathematical Sciences and Center for Statistical Science, Peking University, 5 Yiheyuan Road, Beijing, 100871, P. R. China. ruibinxi@math.pku.edu.cn.
Zhijun XiDepartment of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, No 8, Xishiku Street, Xicheng District, Beijing, 100034, P. R. China. xizhijun@hsc.pku.edu.cn.
Peking University · CNAnnoroad Gene Technology (China) · CNPrecision for Medicine (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression Regulation, NeoplasticMutationB7-H1 AntigenBiomarkers, TumorCarcinoma, Renal CellHigh-Throughput Nucleotide SequencingHumansKidney NeoplasmsNeoplasm StagingPrognosisProportional Hazards ModelsB7-H1 AntigenBiomarkers, TumorCD274 protein, human

Identifiers

PMID31227023
PMCPMC6588887
OpenAlexW2950802753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.